Delysid

Delysid was Sandoz’s name for LSD-25, and its historical importance in the book rests on how the drug moved: from a pharmaceutical source into research centers, treatment rooms, and the hands of guides who carried it between them. The account connects its distribution to the growth of mid-century psychedelic work and its withdrawal to a later break in that circulation. Delysid thus appears not simply as a drug but as a material link between scientific inquiry and therapeutic practice.

Identity and Circulation

The book’s index identifies Delysid as LSD-25 and associates its distribution with the establishment of research hubs. The surrounding narrative shows what such circulation meant in practice. By the late 1950s, Al M. Hubbard traveled among research groups in North America with ampules of Sandoz LSD, sharing supplies as well as clinical knowledge. He visited Humphry Osmond and Abram Hoffer in Weyburn, Saskatchewan, met R. Gordon Wasson in Manhattan, and worked with Betty Eisner, Sidney Cohen, and Oscar Janiger in Los Angeles. The drug could therefore pass through a network of personal contacts and research settings rather than remaining confined to a single laboratory.

Hubbard’s activity connected supply to treatment. In Vancouver, he persuaded Hollywood Hospital to devote an entire wing to treating people with alcohol dependence using LSD; he also established two other treatment facilities in Canada. He sometimes flew celebrities from Los Angeles to Vancouver for sessions, and he regularly conducted LSD treatments at the Canadian centers. The book describes LSD treatment for alcoholism by the Hubbard method as becoming a business in Canada, while noting that Hubbard objected to institutions charging patients more than five hundred dollars for a session. His own approach treated psychedelic therapy as philanthropy, and he spent down his fortune advancing it. Delysid’s significance in this account is consequently inseparable from the question of who could obtain the drug, who administered it, and whether its use was organized as clinical care or as a commercial service.

From Clinical Supply to Experimental Practice

The circulation of Sandoz LSD also carried practice across the boundary between treatment and research. After Myron Stolaroff’s first LSD experience, he began meeting periodically with friends and colleagues at Ampex to discuss spiritual questions and the possibility that LSD might help healthy people realize their potential. Hubbard traveled to Menlo Park to guide the group’s sessions and train members to guide others. Don Allen and Willis Harman joined the circle, and Stolaroff later tried, with Hubbard’s help, to reshape Ampex into a psychedelic corporation. Hubbard held weekly workshops at the company headquarters and administered LSD to executives at a site in the Sierra; the project faltered after the company’s general manager objected to religious images Hubbard brought into his office.

In 1961, Stolaroff left Ampex and, with Harman, established the International Foundation for Advanced Study to investigate LSD’s possible effects on personality and creativity. The foundation secured an FDA research permit and obtained LSD and mescaline from Hubbard. Here the drug supply supported a more formal institutional project: the foundation hired a psychiatrist as medical director and James Fadiman as staff psychologist, while Allen joined as a screener and guide. Delysid’s broader historical role is illuminated by this sequence. A supply passed through Hubbard’s hands into a small group’s exploratory sessions, then into an organization with a permit, staff, and a defined research program.

A Network of Guides and Inherited Methods

The book also traces a later underground therapeutic lineage back to the generation that worked when psychedelic research was still legal in the 1950s and 1960s. The guides interviewed by the narrator could often connect their professional histories to Timothy Leary, Stanislav Grof, Al M. Hubbard, or Leo Zeff. This inheritance included both methods and personal transmission: Hubbard’s role in the account was not limited to providing LSD, since he also guided sessions and trained people to guide others. The drug traveled alongside expertise about how to conduct an experience.

That relationship between material supply and learned practice continued into the later research revival. Myron Stolaroff argued that legitimate research resuming in the late 1990s had developed partly from underground therapists’ accumulated experience as well as from the first wave of research. Some underground guides were recruited to train guides for university trials, and when the Johns Hopkins team investigated music in guided psilocybin sessions, it consulted underground practitioners about their musical practices. These later examples concern psychedelic therapy more broadly, not Delysid specifically, but they show the afterlife of the network in which Sandoz LSD had circulated: methods and people could persist even when the original channels of supply and legal research changed.

Withdrawal and Historical Significance

The book’s index separately records the distribution of LSD-25 under the name Delysid and the withdrawal of Delysid. That pairing gives the drug a clear arc in the history it recounts: circulation helped initiate and connect research centers, while withdrawal marks a contraction in the availability of the pharmaceutical supply. The passages provided do not detail the circumstances of that withdrawal, so its significance here is chiefly structural. A distributed substance had enabled work across hospitals, informal groups, and research organizations; its removal meant that this material channel could no longer be taken for granted.

Delysid therefore stands at the intersection of discovery, access, and institutional change. The book’s examples resist treating psychedelic research as the work of isolated laboratories: ampules were carried between cities, sessions were conducted in hospitals and private settings, and guides learned from one another as well as from formal research. The drug’s movement made those connections tangible. Its history is the history of a supply that helped turn LSD from a laboratory substance into a shared therapeutic and experimental practice—and of the fragility of that practice when the supply was withdrawn.